预约演示
更新于：2026-08-19
Iberdomide
伊伯多胺
更新于：2026-08-19
概要
基本信息
药物类型 降解型分子胶 |
别名 IBER、Iberdomide (USAN/INN)、Iberdomide hydrochloride + [5] |
作用方式 降解剂 |
作用机制 IKZF1 降解剂(DNA结合蛋白IKAROS 降解剂)、IKZF3 降解剂(锌指蛋白Aiolos 降解剂) |
非在研适应症 |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2026-08-13), |
最高研发阶段(中国)申请上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H27N3O5 |
InChIKeyIXZOHGPZAQLIBH-NRFANRHFSA-N |
CAS号1323403-33-3 |
关联
57
项与 伊伯多胺 相关的临床试验NCT07437963
Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
NCT07727668
Feasibility Study of Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07601100
A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant
100 项与 伊伯多胺 相关的临床结果
登录后查看更多信息
100 项与 伊伯多胺 相关的转化医学
登录后查看更多信息
100 项与 伊伯多胺 相关的专利（医药）
登录后查看更多信息
94
项与 伊伯多胺 相关的文献（医药）2026-05-01JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation
Article
作者: Wang, Feng ; Zhao, Xudong ; Yue, Taohua ; Yu, Hang ; Cai, Yunlong ; Rong, Long ; Ma, Yongchen ; Tsao, Chunsheng
ABSTRACT:
Gastric cancer (GC) has poor prognosis and high chemoresistance. This study investigates IKZF3's role in GC progression, oxaliplatin resistance, and underlying mechanisms. IKZF3 expression in GC tissues/cells was assessed using TCGA, qPCR, Western blot, and immunohistochemistry. Prognostic significance was evaluated via Kaplan–Meier analysis. Lentiviral knockdown/overexpression of IKZF3 in HGC27 and AGS cells examined its effects on proliferation, invasion, migration, EMT,tumor stemness and oxaliplatin sensitivity in vitro and in vivo. Additionally, assess whether Iberdomide (an IKZF3 inhibitor) enhances chemosensitivity to oxaliplatin in GC cells in vivo. RNA sequencing (RNA‐seq) identified potential mechanisms. PI3K/AKT/mTOR pathway involvement was tested using PI3K inhibitor LY294002 in rescue experiments. IKZF3 was overexpressed in GC (TCGA/tissue microarrays) and correlated with poor prognosis. Knockdown suppressed proliferation, invasion, migration, EMT, tumor stemness and oxaliplatin resistance in HGC27 cells, while overexpression enhanced these in AGS/HGC27 cells. In vivo, IKZF3 knockdown or inhibitor Iberdomide reduced oxaliplatin resistance. RNA‐seq indicates that IKZF3 knockdown suppressed PI3K/AKT/mTOR pathway activity in HGC27 cells, while overexpression activated it in AGS cells. LY294002 reversed all oncogenic phenotypes and pathway changes induced by IKZF3 modulation. IKZF3 drives GC progression and oxaliplatin resistance by activating PI3K/AKT/mTOR signaling. It is a potential prognostic biomarker and therapeutic target, supporting further development of LY294002 and Iberdomide for GC treatment.
2026-04-29INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review.
Review
作者: Johdi, Nor Adzimah ; Azizan, Elena Aisha ; Rajalingham, Sakthiswary ; Shaharir, Syahrul Sazliyana ; Egan, Audrey Matilda ; Mohd, Rozita ; Zailani, Mohamed Afiq Hidayat
Systemic lupus erythematosus (SLE) is a polygenic autoimmune disorder where genetic diversity drives significant clinical heterogeneity. This review summarizes the current understanding of the roles of genetic polymorphisms in immunological dysregulation, organ-specific manifestations and therapeutic response heterogeneity in individuals with SLE. The literature was obtained from PubMed, EBSCOhost, Web of Science and Scopus. The narrative review comprised 60 publications published within the last 12 years. The research consistently identifies the major histocompatibility complex (MHC) region as the most significant genetic risk factor for the onset of autoimmunity. Genetic variants in STAT4 and IRF5 exacerbate disease progression by facilitating chronic inflammation. These genetic factors are associated with various clinical outcomes, including renal and neuropsychiatric symptoms. Polymorphisms in HLA class II, TLR7 and FBN2 are notably linked to serious consequences, including lupus nephritis (LN). Progress in targeted therapy signifies a transition to personalized medicine with medications such as anifrolumab, litifilimab, iberdomide and Janus kinase (JAK) or Cyclin-Dependent Kinase (CDK) inhibitors, demonstrating potential for targeting pathways associated with the interferon gene signature and STAT4 polymorphisms. Notwithstanding the problems presented by the heterogeneity of SLE, the identification of risk variations is anticipated to enhance predictive and therapeutic biomarkers, hence facilitating more precise and individualized disease management.
2026-01-01Lancet Haematology
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
Article
作者: Roeloffzen, Wilfried W H ; Verkleij, Christie P M ; de Ruijter, Maaike E M ; Wegman, Jurgen ; Zweegman, Sonja ; Nijhof, Inger S ; Smits, Febe ; de Weerdt, Okke ; Nasserinejad, Kazem ; Kerstiens, Ramses ; Smit, Nina ; Franssen, Laurens E ; Mutis, Tuna ; de Kort, Elizabeth A ; Korst, Charlotte L B M ; Croockewit, Alexandra J ; van de Donk, Niels W C J ; Plattel, Wouter ; Levin, Mark-David ; van der Spek, Ellen ; van der Klift, Marjolein ; Groen, Kaz ; Westerman, Matthijs
BACKGROUND:
Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We aimed to evaluate the safety and activity of iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd) in patients with relapsed and refractory multiple myeloma.
METHODS:
The ICON study is a prospective, single-arm, phase 2, open-label study conducted in eight hospitals in the Netherlands. We enrolled patients (aged ≥18 years) with relapsed and refractory multiple myeloma (lenalidomide-refractory) who had received two to four previous lines of therapy and had a WHO performance status of 0-2. Patients were treated with oral iberdomide (1·6 mg/day on days 1-21 of each 28-day cycle), oral low-dose cyclophosphamide (50 mg/day on days 1-28), and oral dexamethasone (40 mg [20 mg in patients age >75 years] once a week) until progression. All patients received thrombosis prophylaxis daily: 80 mg oral aspirin or 100 mg oral carbasalate calcium. Patients with a previous history of venous thromboembolism received only low molecular-weight heparin by subcutaneous injection. The primary endpoint was progression-free survival, defined as time from the start of treatment to the date of progression or death. Activity and safety were assessed in all patients who started treatment. This trial was registered at ClinicalTrials.gov (NCT04392037) and is ongoing.
FINDINGS:
Between Feb 17, 2021, and July 7, 2023, 61 patients were enrolled and received IberCd treatment (29 [48%] were female and 32 [52%] patients were male). The median number of previous lines of therapy was 3 (range 2-5); 52 (85%) patients were triple-class exposed and 27 (44%) had triple-class refractory disease. 50 patients discontinued study treatment, 39 of whom due to progressive disease, but all 61 patients were included in the main analysis population. After a median follow-up of 25·4 months (IQR 19·7-31·6), the median progression-free survival was 17·6 months (one-sided 95% CI 16·6-19·9). In all 61 patients, the most common grade 3-4 adverse events were neutropenia (34 [56%] patients) and infections (21 [34%] patients). Treatment-related serious adverse events were reported in 25 (41%) patients, with infections being the most common (34 [71%] of 48 serious adverse events). Treatment-related death occurred in one (2%) patient due to COVID-19.
INTERPRETATION:
IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments.
FUNDING:
Bristol Myers Squibb.
487
项与 伊伯多胺 相关的新闻（医药）2026-08-18
2026-08-18
100 项与 伊伯多胺 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性多发性骨髓瘤 | 申请上市 | 美国 | 2026-02-17 | |
| 复发性多发性骨髓瘤 | 申请上市 | 美国 | 2026-02-17 | |
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 多发性骨髓瘤 | 申请上市 | 中国 | 2025-12-29 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 美国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 奥地利 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 比利时 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 法国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 韩国 | 2021-10-10 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 西班牙 | 2021-10-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 47 | 獵餘膚夢願構襯鏇築觸(範鹹簾鏇膚衊襯襯餘遞) = DLT (all grade 4 neutropenia) was noted in 3 pts, 2 at DL 1 & 1 at DL -1 願衊簾淵願遞鑰夢醖繭 (鬱鏇鏇積觸製醖糧鬱夢 ) | 积极 | 2026-05-29 | |||
临床2期 | 多发性骨髓瘤 维持 | 38 | 蓋衊膚範齋鏇積憲築構(遞簾範鏇簾選簾艱獵繭) = 鹽夢觸糧鏇壓蓋選製醖 襯淵選膚艱網齋廠蓋糧 (遞壓鬱糧選襯膚齋鑰鹹 ) 更多 | 积极 | 2026-05-29 | ||
临床1/2期 | 多发性骨髓瘤 一线 | 75 | 選顧鏇觸鑰製繭積獵製(選鑰壓觸醖衊網齋夢鬱) = 製鑰遞鹹廠積夢衊選積 顧鏇襯夢憲夢憲簾願製 (鬱願糧膚繭淵鏇廠鏇壓 ) 更多 | 积极 | 2026-05-12 | ||
(Baseline CrCl ≥90 mL/min) | 選顧鏇觸鑰製繭積獵製(選鑰壓觸醖衊網齋夢鬱) = 廠膚積繭繭選衊構淵糧 顧鏇襯夢憲夢憲簾願製 (鬱願糧膚繭淵鏇廠鏇壓 ) 更多 | ||||||
临床2期 | 多发性骨髓瘤 维持 | 15 | 壓觸鏇築築鏇積範鹹齋(繭鑰鑰觸鏇積築顧齋襯) = neutropenia (n=1), rash (n=2), and infections (n=3). 繭蓋構顧製衊齋製廠夢 (鹹艱襯壓鹽鹹築餘鏇積 ) 更多 | 积极 | 2026-02-04 | ||
临床2期 | 61 | (relapsed and refractory multiple myeloma) | 窪蓋遞範蓋糧顧襯鏇鏇(窪淵範範簾製鹹艱鬱積) = 34% of patients experienced infections 鑰憲衊顧顧衊製網鏇鬱 (壓獵鹹繭襯鏇製鏇窪齋 ) 更多 | 积极 | 2026-01-01 | ||
临床1/2期 | 多发性骨髓瘤 t(11;14) | 20 | 淵鏇餘壓顧膚獵艱積齋(襯糧築網憲簾膚顧繭鑰) = 憲築淵製膚餘願衊襯鹽 範淵襯願觸膚鬱簾糧憲 (鏇廠網構醖膚夢衊網廠 ) 更多 | 积极 | 2025-12-06 | ||
临床1期 | 29 | 製範糧範糧廠鬱鏇顧淵(願壓艱鑰齋醖壓積鏇膚) = 蓋鹹餘顧憲鹽簾夢選積 襯積構膚夢憲構膚繭艱 (鏇獵廠襯築願壓遞廠顧, 50.3 ~ 82.6) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 30 | 醖範簾憲鹹襯鑰製積築(遞選醖廠繭窪選範顧窪) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. 範築築願顧選醖憲窪鑰 (蓋構壓蓋顧願醖廠築繭 ) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 多发性骨髓瘤 维持 | 120 | 蓋衊鏇衊壓鹹築糧窪艱(網簾願鬱鏇積構範憲憲) = neutropenia (48% in the 0.75 mg, 58% in the 1.0 mg, and 60% in the 1.3 mg cohorts), followed by infections (8%, 18%, and 18%; mostly respiratory infections). Grade ≥3 rash was more frequent in the 1.3 mg cohort (10%), compared to 0.75 mg (0%) and 1.0 mg (3%) cohorts. There were no grade ≥3 AEs of thrombocytopenia, anemia, or venous thromboembolism. Only 1 of 120 pts (0.8%) developed grade ≥3 neuropathy (1.3 mg), and 1 (0.8%) developed grade 3 diarrhea (1.0 mg). 顧襯繭製廠積願醖遞鑰 (積網網築淵夢餘艱窪製 ) | 积极 | 2025-12-06 | ||
临床2期 | 维持 | 15 | 鹹構憲餘鏇艱鹽衊獵艱(壓廠齋製繭鹽醖簾遞淵) = 醖觸構繭廠鏇繭簾願範 鹽醖餘築範選築繭糧繭 (齋選夢鏇選願蓋繭願製 ) 更多 | 积极 | 2025-12-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用